Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Exchange Rate Effect: 2023-2025

Historic Exchange Rate Effect for Iovance Biotherapeutics (IOVA) over the last 3 years, with Sep 2025 value amounting to -$680,000.

  • Iovance Biotherapeutics' Exchange Rate Effect fell 154.27% to -$680,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$611,000, marking a year-over-year decrease of 116.70%. This contributed to the annual value of -$541,000 for FY2024, which is 80.26% up from last year.
  • Iovance Biotherapeutics' Exchange Rate Effect amounted to -$680,000 in Q3 2025, which was down 192.02% from $739,000 recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Exchange Rate Effect peaked at $3.0 million during Q4 2023, and registered a low of -$3.8 million during Q2 2023.
  • Moreover, its 3-year median value for Exchange Rate Effect was -$308,000 (2024), whereas its average is -$271,400.
  • The largest annual percentage gain for Iovance Biotherapeutics' Exchange Rate Effect in the last 5 years was 691.20% (2025), contrasted with its biggest fall of 154.27% (2025).
  • Over the past 3 years, Iovance Biotherapeutics' Exchange Rate Effect (Quarterly) stood at $3.0 million in 2023, then tumbled by 138.99% to -$1.2 million in 2024, then crashed by 154.27% to -$680,000 in 2025.
  • Its Exchange Rate Effect was -$680,000 in Q3 2025, compared to $739,000 in Q2 2025 and $508,000 in Q1 2025.